Corrigendum to "Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study" [Schizophr. Res. 239 (2022) 83-91].

Autor: Filts Y; Communal Noncommercial Enterprise of Lviv Regional Council, Lviv Regional Clinical Psychiatric Hospital, Lviv, Ukraine., Litman RE; CBH Health LLC, Gaithersburg, MD, USA; Department of Psychiatry, Georgetown University Medical School, Washington, DC, USA., Martínez J; Medical Department, Laboratorios Farmacéuticos ROVI, S.A., Calle Alfonso Gómez, 45-A, 28037 Madrid, Spain., Anta L; Medical Department, Laboratorios Farmacéuticos ROVI, S.A., Calle Alfonso Gómez, 45-A, 28037 Madrid, Spain. Electronic address: lanta@rovi.es., Naber D; Department of Psychiatry and Psychotherapy, Hamburg-Eppendorf University, Hamburg, Germany., Correll CU; Department of Psychiatry Research, The Zucker Hillside Hospital, Glen Oaks, NY, USA; Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Department of Psychiatry and Molecular Medicine, Hempstead, NY, USA; Charité Universitätsmedizin Berlin, Department of Child and Adolescent Psychiatry, Berlin, Germany.
Jazyk: angličtina
Zdroj: Schizophrenia research [Schizophr Res] 2022 Aug; Vol. 246, pp. 258-259. Date of Electronic Publication: 2022 Jul 16.
DOI: 10.1016/j.schres.2022.06.037
Databáze: MEDLINE